FGF23 and X-linked hypophosphatemia: Burosumab, a monoclonal antibody targeted against FGF-23 and approved for TIO and X-linked hypophosphatemia (XLH), has not been extensively studied in patients with chronic kidney disease (CKD) and elevated FGF-23 levels.